Manegold, C., Vansteenkiste, J., Cardenal, F., Schuette, W., Woll, P. J., Ulsperger, E., . . . von Pawel, J. (2012). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Springer US.

Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, Wolfgang Schuette, Penella J. Woll, Ernst Ulsperger, Anne Kerber, Josef Eckmayr, et Joachim von Pawel. Randomized Phase II Study of Three Doses of the Integrin Inhibitor Cilengitide Versus Docetaxel As Second-line Treatment for Patients With Advanced Non-small-cell Lung Cancer. Springer US, 2012.

Manegold, Christian, et al. Randomized Phase II Study of Three Doses of the Integrin Inhibitor Cilengitide Versus Docetaxel As Second-line Treatment for Patients With Advanced Non-small-cell Lung Cancer. Springer US, 2012.